Metagenomi (NASDAQ:MGX) Raised to “Sell” at Wall Street Zen

Metagenomi (NASDAQ:MGX) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Monday.

A number of other research analysts have also issued reports on the company. Wells Fargo & Company reduced their price target on Metagenomi from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings raised Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Metagenomi Stock Performance

MGX opened at $1.20 on Monday. The business’s 50 day moving average is $1.37 and its 200-day moving average is $1.52. The stock has a market cap of $45.18 million, a PE ratio of -0.52 and a beta of 0.64. Metagenomi has a twelve month low of $1.20 and a twelve month high of $3.95.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Metagenomi had a negative return on equity of 51.23% and a negative net margin of 384.61%.The business had revenue of $1.25 million for the quarter, compared to analyst estimates of $5.90 million. As a group, analysts forecast that Metagenomi will post -2.13 EPS for the current year.

Institutional Investors Weigh In On Metagenomi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in Metagenomi by 1,840.0% during the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after purchasing an additional 14,389 shares in the last quarter. Bank of America Corp DE boosted its stake in Metagenomi by 508.5% during the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after purchasing an additional 15,682 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Metagenomi during the 3rd quarter valued at $64,000. Panagora Asset Management Inc. acquired a new position in shares of Metagenomi during the 4th quarter valued at $53,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Metagenomi in the 4th quarter worth $55,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.